Location History:
- Konigstein I. Taunus, DE (2016)
- Königstein i. Taunus, DE (2019)
Company Filing History:
Years Active: 2016-2019
Title: Thomas Lander: Innovator in Prostate Cancer Treatment
Introduction
Thomas Lander, an accomplished inventor based in Königstein I. Taunus, Germany, is known for his contributions to the medical field, particularly in the realm of cancer treatment. With a total of three patents to his name, Lander has been instrumental in advancing innovative therapies aimed at combating prostate cancer.
Latest Patents
Among his most significant inventions is a composition for treating prostate cancer (PCa). This innovative active (immunostimulatory) composition comprises at least one RNA, preferably an mRNA, that encodes two or more antigens capable of eliciting an adaptive immune response in mammals. The specific antigens involved in this groundbreaking composition include Prostate-Specific Antigen (PSA), Prostate-Specific Membrane Antigen (PSMA), Prostate Stem Cell Antigen (PSCA), and Six Transmembrane Epithelial Antigen of the Prostate (STEAP). This invention not only pertains to a vaccine incorporating the active composition but also outlines its use in eliciting an immune response for the treatment of prostate cancer, particularly in cases of neoadjuvant and hormone-refractory types, as well as related disorders. Lander's invention also extends to kits that contain the active (immunostimulatory) composition and/or the vaccine, further facilitating its application in clinical settings.
Career Highlights
Thomas Lander has played a crucial role at CureVac AG, a leading biotechnology company recognized for its dedication to developing transformative mRNA-based therapies. His contributions to the company's mission underscore the vital connection between innovation and real-world health solutions. Lander's inventions reflect a commitment to improving cancer treatment outcomes, emphasizing the importance of immunotherapy in modern medicine.
Collaborations
Lander collaborates with notable experts in the field, including Jochen Probst and Ingmar Hoerr, to harness their collective expertise in advancing new therapeutic solutions. Together, they work toward revolutionizing cancer treatment through innovative scientific endeavors that seek to enhance patient care and survival rates.
Conclusion
Through his inventive work and collaboration, Thomas Lander stands out as a significant figure in the innovation landscape of prostate cancer treatments. His latest patents not only exemplify his visionary approach but also pave the way for new therapeutic possibilities that could transform the lives of patients facing this challenging illness. The ongoing research and development efforts at CureVac AG, bolstered by Lander's expertise, demonstrate a promising avenue for effective cancer treatment innovations.